A Phase 1/2 interventional study of V116 and Pneumovax™23 in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 7th registered.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
Browse Pneumonia, Pneumococcal studies →None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →
Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Median enrollment 431 across the 11 interventional studies, 782 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 4 studies filed under Pneumonia, Pneumococcal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistically significantly greater following vaccination with V116 than those following vaccination with Pneumovax™23.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
Biological: V116
Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
Biological: V116
Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
Biological: Pneumovax™23
Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
Biological: V116
Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2
Biological: Pneumovax™23
Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Polyvalent pneumococcal conjugate vaccine (pPCV), Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PPSV23
Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.
Time frame: Up to 5 days post-vaccination
Phase 1: Percentage of Participants With a Solicited Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was assessed.
Time frame: Up to 5 days post-vaccination
Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.
Time frame: Up to Day 195
Phase 2: Percentage of Participants With a Solicited Injection-site AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.
Time frame: Up to 5 days post-vaccination
Phase 2: Percentage of Participants With a Solicited Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with 1 or more solicited systemic AE was assessed.
Time frame: Up to 5 days post-vaccination
Phase 2: Percentage of Participants With Vaccine-related SAEs
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced at least one SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.
Time frame: Up to Day 293
Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the muliplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116
GMTs for the serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and Pneumovax™23
Serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Serotypes Unique to V116
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Unique Serotypes in V116 and Pneumovax™23
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.
Time frame: Baseline (Day 1) and 30 days postvaccination
Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMCs of Serotype-specific IgG
GMCs for the serotypes in V116 and Pneumovax™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.
Time frame: Baseline (Day 1) and 30 days post vaccination
Phase 2: Serotype-specific IgG GMCs for the Common Serotypes in V116 and Pneumovax™23
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 2: Serotype-specific IgG GMCs for the Serotypes Unique to V116
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: 30 days post vaccination
Phase 2: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and at 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMT/Day 1 GMT.
Time frame: Baseline (Day 1) and 30 days post vaccination
Phase 2: GMFR From Baseline in GMCs of Serotype-specific IgG
GMCs for each serotype common in V116 and Pneumovax™23 were measured using PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC.
Time frame: Baseline (Day 1) and 30 days post vaccination
Phase 2: Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses From Prevaccination (Baseline [Day 1]) to 30 Days Post Vaccination
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model.
Time frame: Baseline (Day 1) and 30 days post vaccination
| Milestone | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|---|---|---|
| Started | 30 | 30 | 30 | 254 | 256 |
| Treated | 30 | 30 | 30 | 254 | 254 |
| Completed | 29 | 29 | 30 | 244 | 247 |
| Not completed | 1 | 1 | 0 | 10 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 7 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.
| Percentage of participants | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Injection site erythema | 10.0 | 23.3 | 20.0 |
| Injection site pain | 73.3 | 76.7 | 56.7 |
| Injection site swelling | 20.0 | 16.7 | 13.3 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was assessed.
| Percentage of participants | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Fatigue | 26.7 | 26.7 | 16.7 |
| Arthralgia | 16.7 | 10.0 | 6.7 |
| Myalgia | 26.7 | 30.0 | 13.3 |
| Headache | 30.0 | 20.0 | 16.7 |
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.
| Percentage of participants | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.
| Percentage of Participants | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Injection site erythema | 8.7 | 6.7 |
| Injection site pain | 46.5 | 37.8 |
| Injection site swelling | 11.0 | 7.9 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with 1 or more solicited systemic AE was assessed.
| Percentage of Participants | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Fatigue | 19.3 | 12.2 |
| Arthralgia | 4.3 | 4.3 |
| Myalgia | 11.0 | 9.4 |
| Headache | 16.9 | 13.4 |
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced at least one SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.
| Percentage of Participants | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Phase 2: Percentage of Participants With Vaccine-related SAEs | 0.0 | 0.0 |
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the muliplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.
| Titers | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 3 | 226.26 (NA to NA) | 226.21 (NA to NA) |
| Serotype 7F | 3535.44 (NA to NA) | 2906.76 (NA to NA) |
| Serotype 19A | 2388.12 (NA to NA) | 2116.13 (NA to NA) |
| Serotype 22F | 8213.56 (NA to NA) | 5192.20 (NA to NA) |
| Serotype 33F | 28129.21 (NA to NA) | 29974.55 (NA to NA) |
| Serotype 8 | 1504.65 (NA to NA) | 1526.78 (NA to NA) |
| Serotype 9N | 10327.15 (NA to NA) | 9106.32 (NA to NA) |
| Serotype 10A | 6062.22 (NA to NA) | 5092.07 (NA to NA) |
| Serotype 11A | 2840.38 (NA to NA) | 1252.27 (NA to NA) |
| Serotype 12F | 2549.45 (NA to NA) | 991.10 (NA to NA) |
| Serotype 17F | 18394.13 (NA to NA) | 11249.90 (NA to NA) |
| Serotype 20A | 9305.32 (NA to NA) | 5068.03 (NA to NA) |
GMTs for the serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| Titers | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 6A | 2757.55 (NA to NA) | 456.97 (NA to NA) |
| Serotype 15A | 11640.00 (NA to NA) | 1711.40 (NA to NA) |
| Serotype 15C | 12611.76 (NA to NA) | 4200.74 (NA to NA) |
| Serotype 16F | 9820.72 (NA to NA) | 539.16 (NA to NA) |
| Serotype 23A | 11554.45 (NA to NA) | 593.91 (NA to NA) |
| Serotype 23B | 3137.15 (NA to NA) | 105.00 (NA to NA) |
| Serotype 24F | 7640.78 (NA to NA) | 238.65 (NA to NA) |
| Serotype 31 | 4461.98 (NA to NA) | 127.84 (NA to NA) |
| Serotype 35B | 15704.65 (NA to NA) | 1745.16 (NA to NA) |
Serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| μg/mL | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 3 | 0.78 (NA to NA) | 0.97 (NA to NA) | 0.86 (NA to NA) |
| Serotype 7F | 3.33 (NA to NA) | 6.39 (NA to NA) | 2.98 (NA to NA) |
| Serotype 19A | 6.29 (NA to NA) | 10.27 (NA to NA) | 4.93 (NA to NA) |
| Serotype 22F | 5.27 (NA to NA) | 7.14 (NA to NA) | 7.16 (NA to NA) |
| Serotype 33F | 8.64 (NA to NA) | 15.19 (NA to NA) | 11.51 (NA to NA) |
| Serotype 8 | 11.33 (NA to NA) | 17.62 (NA to NA) | 17.80 (NA to NA) |
| Serotype 9N | 5.40 (NA to NA) | 8.60 (NA to NA) | 5.26 (NA to NA) |
| Serotype 10A | 8.90 (NA to NA) | 13.13 (NA to NA) | 7.15 (NA to NA) |
| Serotype 11A | 4.50 (NA to NA) | 9.44 (NA to NA) | 5.93 (NA to NA) |
| Serotype 12F | 1.03 (NA to NA) | 2.13 (NA to NA) | 0.99 (NA to NA) |
| Serotype 17F | 11.54 (NA to NA) | 15.71 (NA to NA) | 5.48 (NA to NA) |
| Serotype 20A | 16.44 (NA to NA) | 19.13 (NA to NA) | 9.97 (NA to NA) |
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| μg/mL | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 6A | 6.32 (NA to NA) | 8.08 (NA to NA) | 1.47 (NA to NA) |
| Serotype 15A | 8.87 (NA to NA) | 15.66 (NA to NA) | 1.76 (NA to NA) |
| Serotype 15C | 16.33 (NA to NA) | 18.26 (NA to NA) | 3.71 (NA to NA) |
| Serotype 16F | 1.27 (NA to NA) | 2.44 (NA to NA) | 0.37 (NA to NA) |
| Serotype 23A | 4.02 (NA to NA) | 4.03 (NA to NA) | 0.43 (NA to NA) |
| Serotype 23B | 5.52 (NA to NA) | 7.67 (NA to NA) | 1.61 (NA to NA) |
| Serotype 24F | 3.39 (NA to NA) | 6.79 (NA to NA) | 0.42 (NA to NA) |
| Serotype 31 | 2.68 (NA to NA) | 3.99 (NA to NA) | 0.29 (NA to NA) |
| Serotype 35 | 11.89 (NA to NA) | 16.09 (NA to NA) | 1.29 (NA to NA) |
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| Titers | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 3 | 242.35 (NA to NA) | 259.17 (NA to NA) | 243.66 (NA to NA) |
| Serotype 7F | 4503.32 (NA to NA) | 5672.08 (NA to NA) | 5122.36 (NA to NA) |
| Serotype 19A | 3312.61 (NA to NA) | 4595.55 (NA to NA) | 3475.22 (NA to NA) |
| Serotype 22F | 21336.23 (NA to NA) | 26003.97 (NA to NA) | 12905.25 (NA to NA) |
| Serotype 33F | 62540.43 (NA to NA) | 137389.68 (NA to NA) | 72703.24 (NA to NA) |
| Serotype 8 | 1830.31 (NA to NA) | 2321.18 (NA to NA) | 2598.16 (NA to NA) |
| Serotype 9N | 28204.72 (NA to NA) | 26659.08 (NA to NA) | 24483.35 (NA to NA) |
| Serotype 10A | 10338.92 (NA to NA) | 12377.52 (NA to NA) | 6623.80 (NA to NA) |
| Serotype 11A | 2531.25 (NA to NA) | 3152.05 (NA to NA) | 2836.72 (NA to NA) |
| Serotype 12F | 5171.95 (NA to NA) | 7279.62 (NA to NA) | 3036.31 (NA to NA) |
| Serotype 17F | 48838.60 (NA to NA) | 51152.97 (NA to NA) | 24816.34 (NA to NA) |
| Serotype 20A | 13910.60 (NA to NA) | 17799.33 (NA to NA) | 11430.20 (NA to NA) |
GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| Titers | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 6A | 7182.41 (NA to NA) | 7407.66 (NA to NA) | 513.88 (NA to NA) |
| Serotype 15A | 19337.39 (NA to NA) | 24580.49 (NA to NA) | 2615.98 (NA to NA) |
| Serotype 15C | 20743.02 (NA to NA) | 27242.11 (NA to NA) | 9728.58 (NA to NA) |
| Serotype 16F | 11120.97 (NA to NA) | 17201.69 (NA to NA) | 2931.40 (NA to NA) |
| Serotype 23A | 26267.17 (NA to NA) | 36793.08 (NA to NA) | 1908.80 (NA to NA) |
| Serotype 23B | 5258.43 (NA to NA) | 8684.75 (NA to NA) | 220.48 (NA to NA) |
| Serotype 24F | 7593.39 (NA to NA) | 11867.21 (NA to NA) | 381.95 (NA to NA) |
| Serotype 31 | 7417.79 (NA to NA) | 7453.48 (NA to NA) | 128.36 (NA to NA) |
| Serotype 35B | 21103.18 (NA to NA) | 23826.47 (NA to NA) | 3044.94 (NA to NA) |
GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.
| Ratio | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 3 | 12.90 (8.95 to 18.59) | 10.68 (6.27 to 18.18) | 10.01 (6.62 to 15.14) |
| Serotype 7F | 15.64 (6.94 to 35.23) | 19.68 (9.96 to 38.87) | 34.18 (15.67 to 74.56) |
| Serotype 19A | 12.26 (7.03 to 21.38) | 18.34 (10.32 to 32.60) | 14.92 (7.84 to 28.42) |
| Serotype 22F | 92.21 (38.88 to 218.70) | 81.76 (32.42 to 206.23) | 32.64 (14.59 to 73.04) |
| Serotype 33F | 17.68 (10.86 to 28.78) | 34.83 (21.63 to 56.09) | 20.24 (11.07 to 37.02) |
| Serotype 8 | 39.67 (21.83 to 72.09) | 50.01 (25.73 to 97.20) | 72.24 (38.21 to 136.59) |
| Serotype 9N | 22.91 (10.93 to 48.00) | 19.80 (8.34 to 47.04) | 27.38 (13.87 to 54.03) |
| Serotype 10A | 12.69 (5.39 to 29.87) | 18.21 (8.76 to 37.85) | 10.35 (5.00 to 21.41) |
| Serotype 11A | 7.46 (3.40 to 16.39) | 8.23 (4.46 to 15.21) | 7.64 (4.20 to 13.93) |
| Serotype 12F | 360.69 (192.76 to 674.93) | 448.73 (243.29 to 827.65) | 162.71 (85.83 to 308.43) |
| Serotype 17F | 36.57 (17.73 to 75.45) | 37.33 (20.19 to 69.04) | 20.54 (11.70 to 36.08) |
| Serotype 20A | 15.67 (8.21 to 29.92) | 19.20 (10.52 to 35.07) | 14.91 (8.60 to 25.83) |
| Serotype 6A | 311.54 (171.83 to 565.18) | 375.42 (194.76 to 723.64) | 20.95 (9.44 to 46.47) |
| Serotype 15A | 31.56 (12.49 to 79.74) | 29.31 (13.47 to 63.79) | 5.53 (2.96 to 10.35) |
| Serotype 15C | 37.97 (13.68 to 105.40) | 58.39 (20.58 to 165.67) | 10.58 (6.14 to 18.23) |
| Serotype 16F | 16.82 (7.30 to 38.75) | 25.99 (10.54 to 64.09) | 4.30 (2.59 to 7.12) |
| Serotype 23A | 380.08 (136.77 to 1056.21) | 269.90 (86.95 to 837.80) | 17.52 (6.87 to 44.65) |
| Serotype 23B | 99.58 (36.09 to 274.72) | 157.02 (61.06 to 403.76) | 5.39 (2.92 to 9.95) |
| Serotype 24F | 14.86 (5.86 to 37.70) | 23.51 (9.64 to 57.34) | 1.24 (0.76 to 2.03) |
| Serotype 31 | 95.53 (36.62 to 249.17) | 94.51 (39.26 to 227.50) | 3.23 (1.52 to 6.86) |
| Serotype 35B | 13.68 (7.26 to 25.79) | 12.56 (8.48 to 18.61) | 1.73 (1.45 to 2.06) |
| Serotype 6C | 41.71 (14.41 to 120.73) | 65.05 (23.86 to 177.35) | 2.82 (1.46 to 5.43) |
| Serotype 15B | 78.68 (25.58 to 242.03) | 89.25 (30.60 to 260.27) | 33.11 (13.27 to 82.61) |
| Serotype 20B | 3.78 (1.97 to 7.26) | 4.17 (2.05 to 8.47) | 5.01 (2.46 to 10.23) |
GMCs for the serotypes in V116 and Pneumovax™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.
| Ratio | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 |
|---|---|---|---|
| Serotype 3 | 5.36 (3.90 to 7.35) | 5.94 (4.05 to 8.71) | 4.97 (3.39 to 7.27) |
| Serotype 7F | 8.38 (5.30 to 13.25) | 16.00 (10.28 to 24.90) | 7.44 (5.05 to 10.97) |
| Serotype 19A | 4.67 (3.03 to 7.21) | 7.28 (4.63 to 11.45) | 3.66 (2.66 to 5.04) |
| Serotype 22F | 19.51 (11.64 to 32.69) | 21.83 (13.51 to 35.29) | 24.34 (12.30 to 48.18) |
| Serotype 33F | 9.33 (5.62 to 15.49) | 16.28 (10.36 to 25.58) | 11.75 (7.66 to 18.03) |
| Serotype 8 | 13.86 (8.94 to 21.49) | 22.89 (15.29 to 34.27) | 25.99 (15.35 to 44.00) |
| Serotype 9N | 12.90 (8.60 to 19.36) | 20.85 (13.11 to 33.16) | 14.37 (8.41 to 24.55) |
| Serotype 10A | 11.36 (6.61 to 19.52) | 16.10 (9.76 to 26.57) | 9.58 (6.94 to 13.24) |
| Serotype 11A | 2.71 (1.70 to 4.33) | 7.18 (3.96 to 13.02) | 5.17 (3.24 to 8.24) |
| Serotype 12F | 10.35 (6.36 to 16.85) | 22.71 (13.35 to 38.61) | 9.75 (5.37 to 17.71) |
| Serotype 17F | 19.23 (11.44 to 32.34) | 22.52 (14.61 to 34.73) | 10.07 (6.80 to 14.91) |
| Serotype 20A | 10.81 (6.67 to 17.50) | 11.18 (7.38 to 16.93) | 5.60 (3.58 to 8.77) |
| Serotype 6A | 23.58 (12.37 to 44.95) | 29.48 (18.01 to 48.26) | 5.66 (3.29 to 9.76) |
| Serotype 15A | 14.61 (8.07 to 26.45) | 28.84 (17.91 to 46.44) | 3.02 (1.87 to 4.88) |
| Serotype 15C | 31.93 (18.64 to 54.69) | 37.55 (20.18 to 69.88) | 7.94 (5.56 to 11.36) |
| Serotype 16F | 4.39 (2.71 to 7.11) | 10.80 (7.22 to 16.15) | 1.69 (1.16 to 2.45) |
| Serotype 23A | 23.43 (12.21 to 44.99) | 22.53 (11.84 to 42.86) | 2.75 (1.83 to 4.13) |
| Serotype 23B | 9.03 (4.99 to 16.36) | 15.56 (8.88 to 27.27) | 2.66 (1.92 to 3.68) |
| Serotype 24F | 11.18 (5.18 to 24.13) | 19.44 (11.30 to 33.47) | 1.26 (0.79 to 2.03) |
| Serotype 31 | 12.83 (7.24 to 22.75) | 19.71 (12.90 to 30.13) | 1.77 (1.19 to 2.63) |
| Serotype 35B | 9.77 (5.70 to 16.73) | 11.33 (7.01 to 18.31) | 0.96 (0.86 to 1.06) |
| Serotype 6C | 6.52 (3.64 to 11.70) | 9.48 (5.47 to 16.42) | 2.22 (1.61 to 3.07) |
| Serotype 15B | 12.54 (6.73 to 23.36) | 11.96 (6.32 to 22.65) | 8.05 (5.67 to 11.42) |
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| μg/mL | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 3 | 0.78 (NA to NA) | 0.72 (NA to NA) |
| Serotype 7F | 4.98 (NA to NA) | 4.07 (NA to NA) |
| Serotype 19A | 7.77 (NA to NA) | 6.26 (NA to NA) |
| Serotype 22F | 3.81 (NA to NA) | 2.79 (NA to NA) |
| Serotype 33F | 11.89 (NA to NA) | 13.82 (NA to NA) |
| Serotype 8 | 9.86 (NA to NA) | 10.30 (NA to NA) |
| Serotype 9N | 7.18 (NA to NA) | 5.51 (NA to NA) |
| Serotype 10A | 10.78 (NA to NA) | 5.89 (NA to NA) |
| Serotype 11A | 5.16 (NA to NA) | 3.35 (NA to NA) |
| Serotype 12F | 1.56 (NA to NA) | 0.68 (NA to NA) |
| Serotype 17F | 12.85 (NA to NA) | 7.06 (NA to NA) |
| Serotype 20A | 20.59 (NA to NA) | 9.09 (NA to NA) |
Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| μg/mL | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 6A | 4.06 (NA to NA) | 1.07 (NA to NA) |
| Serotype 15A | 13.14 (NA to NA) | 1.71 (NA to NA) |
| Serotype 15C | 11.91 (NA to NA) | 3.62 (NA to NA) |
| Serotype 16F | 2.17 (NA to NA) | 0.25 (NA to NA) |
| Serotype 23A | 3.32 (NA to NA) | 0.42 (NA to NA) |
| Serotype 23B | 5.18 (NA to NA) | 0.92 (NA to NA) |
| Serotype 24F | 6.11 (NA to NA) | 0.25 (NA to NA) |
| Serotype 31 | 3.15 (NA to NA) | 0.31 (NA to NA) |
| Serotype 35B | 24.55 (NA to NA) | 1.34 (NA to NA) |
GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and at 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMT/Day 1 GMT.
| Ratio | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 3 | 12.03 (10.04 to 14.41) | 10.96 (9.25 to 13.00) |
| Serotype 7F | 31.07 (22.87 to 42.22) | 22.52 (17.23 to 29.45) |
| Serotype 19A | 13.05 (10.22 to 16.66) | 10.26 (8.31 to 12.67) |
| Serotype 22F | 52.66 (37.40 to 74.14) | 46.34 (33.34 to 64.41) |
| Serotype 33F | 13.47 (10.47 to 17.32) | 14.04 (11.23 to 17.53) |
| Serotype 8 | 39.06 (30.34 to 50.28) | 40.06 (31.59 to 50.80) |
| Serotype 9N | 33.51 (24.38 to 46.04) | 29.38 (21.67 to 39.82) |
| Serotype 10A | 12.34 (8.79 to 17.31) | 8.12 (6.03 to 10.94) |
| Serotype 11A | 33.21 (25.13 to 43.88) | 12.29 (9.41 to 16.05) |
| Serotype 12F | 150.08 (112.83 to 199.61) | 57.03 (42.59 to 76.35) |
| Serotype 17F | 40.71 (30.35 to 54.60) | 25.68 (19.56 to 33.73) |
| Serotype 20A | 20.48 (16.11 to 26.02) | 12.16 (9.58 to 15.43) |
| Serotype 6A | 79.16 (58.28 to 107.51) | 11.30 (8.42 to 15.16) |
| Serotype 15A | 26.66 (20.16 to 35.25) | 3.93 (3.18 to 4.87) |
| Serotype 15C | 65.18 (46.91 to 90.58) | 23.73 (16.98 to 33.15) |
| Serotype 16F | 56.50 (41.53 to 76.85) | 3.54 (2.61 to 4.81) |
| Serotype 23A | 237.14 (166.28 to 338.22) | 10.65 (7.42 to 15.29) |
| Serotype 23B | 97.79 (71.94 to 132.92) | 4.62 (3.58 to 5.96) |
| Serotype 24F | 48.78 (35.07 to 67.84) | 1.52 (1.18 to 1.97) |
| Serotype 31 | 92.00 (66.09 to 128.07) | 3.25 (2.51 to 4.21) |
| Serotype 35B | 12.41 (10.08 to 15.27) | 1.53 (1.33 to 1.75) |
| Serotype 6C | 19.41 (13.65 to 27.61) | 4.24 (3.09 to 5.84) |
| Serotype 15B | 24.32 (17.88 to 33.08) | 25.73 (19.14 to 34.58) |
| Serotype 20B | 7.21 (5.68 to 9.17) | 5.35 (4.08 to 7.01) |
GMCs for each serotype common in V116 and Pneumovax™23 were measured using PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC.
| Ratio | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 3 | 5.23 (4.52 to 6.06) | 4.56 (3.98 to 5.21) |
| Serotype 7F | 9.96 (8.40 to 11.81) | 8.28 (7.06 to 9.71) |
| Serotype 19A | 5.29 (4.51 to 6.21) | 4.12 (3.60 to 4.71) |
| Serotype 22F | 12.45 (10.07 to 15.39) | 9.04 (7.53 to 10.86) |
| Serotype 33F | 9.94 (8.26 to 11.97) | 11.63 (9.87 to 13.71) |
| Serotype 8 | 14.53 (11.92 to 17.72) | 15.51 (13.06 to 18.40) |
| Serotype 9N | 17.77 (14.62 to 21.61) | 11.80 (9.92 to 14.04) |
| Serotype 10A | 17.32 (14.41 to 20.82) | 9.29 (7.92 to 10.90) |
| Serotype 11A | 7.71 (6.56 to 9.07) | 4.72 (4.12 to 5.41) |
| Serotype 12F | 13.72 (11.13 to 16.91) | 6.14 (5.11 to 7.37) |
| Serotype 17F | 20.26 (17.03 to 24.11) | 11.11 (9.54 to 12.95) |
| Serotype 20A | 14.95 (12.53 to 17.84) | 6.30 (5.41 to 7.33) |
| Serotype 6A | 13.35 (10.90 to 16.35) | 3.56 (3.03 to 4.19) |
| Serotype 15A | 23.94 (19.89 to 28.81) | 3.02 (2.63 to 3.47) |
| Serotype 15C | 22.35 (18.49 to 27.01) | 7.28 (6.17 to 8.60) |
| Serotype 16F | 12.42 (10.62 to 14.52) | 1.51 (1.37 to 1.66) |
| Serotype 23A | 20.27 (16.82 to 24.43) | 2.66 (2.30 to 3.06) |
| Serotype 23B | 13.50 (11.25 to 16.21) | 2.51 (2.21 to 2.85) |
| Serotype 24F | 25.20 (20.48 to 31.02) | 1.08 (1.02 to 1.14) |
| Serotype 31 | 15.89 (13.47 to 18.76) | 1.62 (1.46 to 1.81) |
| Serotype 35B | 18.72 (15.89 to 22.05) | 1.04 (0.98 to 1.10) |
| Serotype 6C | 5.78 (4.79 to 6.97) | 1.67 (1.52 to 1.85) |
| Serotype 15B | 9.95 (8.28 to 11.95) | 8.87 (7.52 to 10.47) |
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model.
| Percentage of Participants | Phase 2: V116 | Phase 2: Pneumovax™23 |
|---|---|---|
| Serotype 3 | 74.8 (68.8 to 80.2) | 75.7 (69.7 to 81.1) |
| Serotype 7F | 74.2 (68.1 to 79.6) | 77.0 (71.1 to 82.2) |
| Serotype 19A | 66.9 (60.6 to 72.9) | 67.1 (60.7 to 73.1) |
| Serotype 22F | 81.3 (75.7 to 86.1) | 79.3 (73.5 to 84.3) |
| Serotype 33F | 68.4 (62.0 to 74.3) | 75.7 (69.5 to 81.1) |
| Serotype 8 | 80.9 (75.2 to 85.7) | 85.5 (80.3 to 89.7) |
| Serotype 9N | 77.3 (71.3 to 82.5) | 79.5 (73.7 to 84.5) |
| Serotype 10A | 59.9 (52.4 to 67.1) | 55.2 (47.5 to 62.7) |
| Serotype 11A | 80.3 (74.6 to 85.1) | 62.9 (56.3 to 69.2) |
| Serotype 12F | 90.2 (85.4 to 93.8) | 82.9 (77.3 to 87.6) |
| Serotype 17F | 85.2 (80.1 to 89.5) | 80.9 (75.2 to 85.7) |
| Serotype 20A | 83.6 (78.3 to 88.1) | 69.4 (63.0 to 75.2) |
| Serotype 6A | 83.2 (77.8 to 87.7) | 58.8 (52.2 to 65.2) |
| Serotype 15A | 86.6 (81.3 to 90.8) | 39.3 (32.7 to 46.3) |
| Serotype 15C | 88.5 (83.6 to 92.3) | 71.0 (64.4 to 76.9) |
| Serotype 16F | 85.4 (80.1 to 89.7) | 30.2 (24.2 to 36.8) |
| Serotype 23A | 93.3 (89.1 to 96.3) | 48.7 (41.6 to 55.9) |
| Serotype 23B | 87.4 (82.4 to 91.4) | 40.4 (33.9 to 47.0) |
| Serotype 24F | 82.8 (77.2 to 87.5) | 15.3 (10.6 to 21.0) |
| Serotype 31 | 86.6 (81.3 to 90.8) | 30.1 (24.0 to 36.9) |
| Serotype 35B | 73.2 (67.0 to 78.9) | 11.3 (7.5 to 16.2) |
| Serotype 6C | 58.4 (51.8 to 64.9) | 33.8 (27.7 to 40.3) |
| Serotype 15B | 71.0 (64.6 to 76.8) | 75.3 (69.1 to 80.8) |
| Serotype 20B | 52.8 (46.2 to 59.4) | 44.1 (37.5 to 50.8) |
Collected over Up to approximately 195 days post-vaccination for Phase 1 and up to approximately 293 days post-vaccination for Phase 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: V116 0.5 mL | 0/30 (0%) | 0/30 (0%) | 23/30 (76.7%) |
| Phase 1: V116 1.0 mL | 0/30 (0%) | 0/30 (0%) | 24/30 (80%) |
| Phase 1: PPSV23 | 0/30 (0%) | 0/30 (0%) | 21/30 (70%) |
| Phase 2: V116 | 1/254 (0.4%) | 4/254 (1.6%) | 159/254 (62.6%) |
| Phase 2: PPSV23 | 0/256 (0%) | 3/254 (1.2%) | 133/254 (52.4%) |
| Event | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: PPSV23 | Phase 2: V116 | Phase 2: PPSV23 |
|---|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/30 | 0/30 | 0/30 | 0/254 | 1/254 |
| Atrial fibrillationCardiac disorders | 0/30 | 0/30 | 0/30 | 1/254 | 0/254 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/30 | 0/30 | 0/30 | 1/254 | 0/254 |
| COVID-19Infections and infestations | 0/30 | 0/30 | 0/30 | 1/254 | 0/254 |
| Staphylococcal bacteraemiaInfections and infestations | 0/30 | 0/30 | 0/30 | 0/254 | 1/254 |
| Urinary tract infectionInfections and infestations | 0/30 | 0/30 | 0/30 | 0/254 | 1/254 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/30 | 0/30 | 0/30 | 1/254 | 0/254 |
| Cervical radiculopathyNervous system disorders | 0/30 | 0/30 | 0/30 | 1/254 | 0/254 |
| Acute kidney injuryRenal and urinary disorders | 0/30 | 0/30 | 0/30 | 0/254 | 1/254 |
| Event | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: PPSV23 | Phase 2: V116 | Phase 2: PPSV23 |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 22/30 | 23/30 | 17/30 | 118/254 | 96/254 |
| HeadacheNervous system disorders | 10/30 | 6/30 | 5/30 | 47/254 | 41/254 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/30 | 9/30 | 4/30 | 33/254 | 26/254 |
| FatigueGeneral disorders | 8/30 | 8/30 | 5/30 | 50/254 | 32/254 |
| Injection site erythemaGeneral disorders | 3/30 | 7/30 | 6/30 | 26/254 | 17/254 |
| Injection site swellingGeneral disorders | 6/30 | 5/30 | 4/30 | 30/254 | 20/254 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/30 | 3/30 | 2/30 | 11/254 | 12/254 |
| Injection site bruisingGeneral disorders | 0/30 | 2/30 | 1/30 | 1/254 | 0/254 |
| PyrexiaGeneral disorders | 0/30 | 0/30 | 2/30 | 1/254 | 0/254 |
| Upper respiratory tract infectionInfections and infestations | 1/30 | 2/30 | 0/30 | 0/254 | 0/254 |
| Age, Continuous(years) | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 | Phase 2: V116 | Phase 2: Pneumovax™23 | Total |
|---|---|---|---|---|---|---|
| Mean | 37.8 ± 7.4 | 34.7 ± 8.9 | 35.2 ± 8.2 | 61.3 ± 7.0 | 61.2 ± 7.3 | 57.5 ± 11.7 |
| Sex: Female, Male(Participants) | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 | Phase 2: V116 | Phase 2: Pneumovax™23 | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 19 | 24 | 142 | 140 | 341 |
| Male | 14 | 11 | 6 | 112 | 116 | 259 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 | Phase 2: V116 | Phase 2: Pneumovax™23 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 13 | 13 | 107 | 107 | 254 |
| Not Hispanic or Latino | 16 | 17 | 17 | 147 | 147 | 344 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Phase 1: V116 0.5 mL | Phase 1: V116 1.0 mL | Phase 1: Pneumovax™23 | Phase 2: V116 | Phase 2: Pneumovax™23 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 1 | 3 |
| Asian | 1 | 1 | 2 | 2 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 6 | 4 | 4 | 25 | 30 | 69 |
| White | 23 | 23 | 24 | 224 | 220 | 514 |
| More than one race | 0 | 2 | 0 | 0 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2019 to primary completion in Jul 2021, 19 months.
Results were first posted in Aug 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine